Company profile BEAM
Beam Therapeutics Inc
beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing... point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team: a community of fearless innovators rigorous and honest in our research listening with open minds committed to each other
Show More
After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 115 |
| 2019 | 246 113.9% QoQ | 235 -4.5% QoQ | 290 23.4% QoQ | 361 213.9% YoY 24.5% QoQ |
| 2020 | 481 95.5% YoY 33.2% QoQ | 368 56.6% YoY -23.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2021 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2022 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2023 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of beam therapeutics -stock -ipo was 8.03 per week. The last year interest of beam therapeutics -stock -ipo compared to the last 5 years has changed by -100.0%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -100.0%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
After 39 days of this quarter the interest is at 75.0. Based on that we can calculate that during remaining 52 days it will total up to 175.0. beam testing expected interest is significantly lower compared to previous quarter (-50.8%) and same quarter last year (-43.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 124 | 253 104.0% QoQ | 295 16.6% QoQ | 220 -25.4% QoQ |
| 2020 | 310 150.0% YoY 40.9% QoQ | 208 -17.8% YoY -32.9% QoQ | 267 -9.5% YoY 28.4% QoQ | 305 38.6% YoY 14.2% QoQ |
| 2021 | 224 -27.7% YoY -26.6% QoQ | 269 29.3% YoY 20.1% QoQ | 175 -34.5% YoY -34.9% QoQ | 189 -38.0% YoY 8.0% QoQ |
| 2022 | 396 76.8% YoY 109.5% QoQ | 320 19.0% YoY -19.2% QoQ | 345 97.1% YoY 7.8% QoQ | 187 -1.1% YoY -45.8% QoQ |
| 2023 | 307 -22.5% YoY 64.2% QoQ | 184 -42.5% YoY -40.1% QoQ | 276 -20.0% YoY 50.0% QoQ | 356 90.4% YoY 29.0% QoQ |
| 2024 | 75 -75.6% YoY -78.9% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of beam testing was 20.25 per week. The last year interest of beam testing compared to the last 5 years has changed by 7.51%. The interest for beam testing is seasonal. The last year interest is quite higher compared to 5 years ago. It has increased by 19.68%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
After 39 days of this quarter the interest is at 20.0. Based on that we can calculate that during remaining 52 days it will total up to 47.0. beam gene expected interest is significantly lower compared to previous quarter (-73.1%) and same quarter last year (-74.9%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 104 | 81 -22.1% QoQ | 88 8.6% QoQ | 207 135.2% QoQ |
| 2020 | 197 89.4% YoY -4.8% QoQ | 140 72.8% YoY -28.9% QoQ | 176 100.0% YoY 25.7% QoQ | 282 36.2% YoY 60.2% QoQ |
| 2021 | 101 -48.7% YoY -64.2% QoQ | 203 45.0% YoY 101.0% QoQ | 74 -58.0% YoY -63.5% QoQ | 65 -77.0% YoY -12.2% QoQ |
| 2022 | 223 120.8% YoY 243.1% QoQ | 111 -45.3% YoY -50.2% QoQ | 208 181.1% YoY 87.4% QoQ | 51 -21.5% YoY -75.5% QoQ |
| 2023 | 187 -16.1% YoY 266.7% QoQ | 217 95.5% YoY 16.0% QoQ | 81 -61.1% YoY -62.7% QoQ | 175 243.1% YoY 116.0% QoQ |
| 2024 | 20 -89.3% YoY -88.6% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of beam gene was 11.46 per week. The last year interest of beam gene compared to the last 5 years has changed by 3.84%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 5.59%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for BEAM
Earnings date: 2024-02-27 After close
Company name: Beam Therapeutics Inc
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-05-13T18:34:28Z
Analyst Upgrades
Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $392026-05-13T11:49:00-04:00
PR Newswire
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-12026-05-13T11:00:00Z
GlobeNewswire
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference2026-05-12T13:30:00Z
GlobeNewswire
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA20262026-05-07T11:00:00Z
GlobeNewswire
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates2026-04-01T21:12:19Z
GlobeNewswire
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine2026-03-26T15:35:48Z
Analyst Upgrades
Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $682026-03-25T11:00:00Z
GlobeNewswire
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development2026-02-25T15:12:09Z
Analyst Upgrades
RBC Capital Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $262026-02-25T13:24:53Z
Analyst Upgrades
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $652026-02-24T12:01:00Z
GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)2026-02-24T12:00:00Z
GlobeNewswire
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street2026-02-23T21:00:00Z
GlobeNewswire
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program2026-02-20T20:51:31Z
Analyst Upgrades
Canaccord Genuity Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $742026-01-21T15:28:30Z
Analyst Upgrades
Bernstein Maintains Outperform on Beam Therapeutics, Raises Price Target to $41